These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 34759817)

  • 21. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
    Weis TM; Hough S; Reddy HG; Daignault-Newton S; Kalemkerian GP
    J Oncol Pharm Pract; 2020 Apr; 26(3):564-571. PubMed ID: 31238808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Wang S; Lv H; Yu J; Chen M
    Int Immunopharmacol; 2024 Apr; 131():111884. PubMed ID: 38518592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
    Liang J; Li M; Sui Q; Hu Z; Bian Y; Huang Y; Zhan C; Jiang W; Wang Q; Tan L
    Transl Lung Cancer Res; 2020 Aug; 9(4):1302-1323. PubMed ID: 32953506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
    Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
    J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
    [No Abstract]   [Full Text] [Related]  

  • 30. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
    Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
    Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.
    Wu C; Li W; Tao H; Zhang X; Xin Y; Song R; Wang K; Zuo L; Cai Y; Wu H; Hui W
    Crit Rev Oncol Hematol; 2024 Jan; 193():104195. PubMed ID: 37931769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.
    Trinh S; Le A; Gowani S; La-Beck NM
    Asia Pac J Oncol Nurs; 2019; 6(2):154-160. PubMed ID: 30931360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
    Ebinama U; Sheshadri A; Anand K; Swaminathan I
    J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
    Kurokawa K; Mitsuishi Y; Shimada N; Kawakami Y; Miura K; Miyawaki T; Asao T; Ko R; Shukuya T; Shibayama R; Nojiri S; Takahashi K
    BMC Cancer; 2022 Oct; 22(1):1047. PubMed ID: 36203123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
    De Velasco G; Je Y; Bossé D; Awad MM; Ott PA; Moreira RB; Schutz F; Bellmunt J; Sonpavde GP; Hodi FS; Choueiri TK
    Cancer Immunol Res; 2017 Apr; 5(4):312-318. PubMed ID: 28246107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.
    Kong Q; Wang H; Ren X; Zhuo Y; Peng J
    Cancer Med; 2023 Oct; 12(19):19491-19499. PubMed ID: 37724594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.